Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 1,729 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oruka Therapeutics Price Performance

Shares of ORKA traded down $1.03 during trading hours on Monday, hitting $68.86. The company’s stock had a trading volume of 1,002,319 shares, compared to its average volume of 1,071,721. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -35.49 and a beta of -0.25. The business has a 50 day simple moving average of $63.40 and a two-hundred day simple moving average of $44.04. Oruka Therapeutics, Inc. has a 52-week low of $10.77 and a 52-week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. Research analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently bought and sold shares of ORKA. Legal & General Group Plc bought a new stake in Oruka Therapeutics during the second quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada lifted its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Oruka Therapeutics during the fourth quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in Oruka Therapeutics during the third quarter valued at approximately $39,000. 56.44% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on ORKA shares. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Monday, April 27th. Stifel Nicolaus boosted their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $131.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.